Table 3. Clinical characteristics of inpatients with COVID-19.
Patient# | Disease severitya | Age (y) | Sex | Past medical history | Therapy | Outcome | |
---|---|---|---|---|---|---|---|
1 | Mild | 65 | M | Hepatic cancer, Rheumatoid arthritis | N/A | N/A | cure/discharge |
2 | Mild | 63 | M | None known | N/A | N/A | cure/discharge |
3 | Mild | 72 | M | None known | N/A | Favipiravir, Ciclesonide, DEX | cure/discharge |
4 | Mild | 82 | M | Bile duct cancer | N/A | Favipiravir | cure/discharge |
5 | Moderate | 64 | M | post-Pancreatic Cancer | N/A | N/A | cure/discharge |
6 | Moderate | 78 | M | None known | N/A | Ciclesonide, Favipiravir | cure/discharge |
7 | Moderate | 41 | M | Lung sarcoidosis | N/A | Ciclesonide, Favipiravir | cure/discharge |
8 | Moderate | 76 | M | Prostatic hypertrophy | N/A | Ciclesonide, Favipiravir, Heparin | cure/discharge |
9 | Moderate | 37 | M | None known | N/A | Ciclesonide, Favipiravir | cure/discharge |
10 | Moderate | 59 | M | Hypertension, Hyperlipidemia | N/A | Ciclesonide, Favipiravir | cure/discharge |
11 | Moderate | 71 | F | Hyperlipidemia, Diabetes | N/A | Ciclesonide, Favipiravir, Heparin | cure/discharge |
12 | Moderate | 75 | F | Hypertension, Hyperlipidemia, Angina | N/A | Ciclesonide, Favipiravir | cure/discharge |
13 | Moderate | 18 | F | None known | N/A | N/A | cure/discharge |
14 | Moderate | 80 | F | Hypertension | N/A | Heparin | cure/discharge |
15 | Severe | 78 | M | Diabetes, Rheumatoid arthritis | O2 | Heparin | cure/discharge |
16 | Severe | 57 | M | Hyponatremia | O2 | Ciclesonide, Favipiravir | cure/discharge |
17 | Severe | 64 | M | Urinary stone | N/A | N/A | cure/discharge |
18 | Severe | 67 | M | Fatty liver, Kidney stones | O2 | Ciclesonide, Favipiravir, Heparin | cure/discharge |
19 | Severe | 46 | M | Diabetes, Angina, Stiff-person syndrome | O2 | Favipiravir, Heparin, mPSL, PSL, Remdesivir | cure/discharge |
20 | Severe | 84 | M | Colon cancer, Parkinson, Dementia | O2 | Heparin | cure/discharge |
21 | Severe | 84 | M | Hypertension, Lung cancer, Renal failure | O2 | CHDF, Ciclesonide, DEX, FFP, Favipiravir, mPSL, Plasmapheresis, PSL | death |
22 | Critical | 67 | M | Hypertension, Renal failure | Ventilation | CHDF, Ciclesonide, FFP, mPSL, Plasmapheresis | death |
23 | Critical | 77 | M | Hypertension, Diabetes, Prostate cancer | Ventilation | CHDF, Favipiravir, FFP, Heparin, mPSL, Plasmapheresis, PSL, Remdesivir | death |
Patients tested 3 times or more were included.
aWHO criteria.
Abbreviations: CHDF, Continuous hemodiafiltration; DEX, Dexamethasone; FFP, fresh frozen plasma; O2, Oxygen inhalation; PSL, prednisolone; N/A, not applicable.